# ResMed Inc. (RMD) Stock Analysis: A Look at a 17.83% Potential Upside for Healthcare Investors

- Link: https://www.directorstalkinterviews.com/resmed-inc-rmd-stock-analysis-a-look-at-a-17-83-potential-upside-for-healthcare-investors/4121258964
- Published: 2026-08-03T10:22:16+01:00
- Author: Madison Wilson

ResMed Inc. (NYSE: RMD), a prominent player in the healthcare sector, is making 
waves in the medical instruments and supplies industry. With a solid market capitalization
of $30.6 billion, the company is well-positioned in the United States and globally,
driving innovation in respiratory health and residential care software.

Currently trading at $210.98, ResMed’s stock has experienced a slight uptick of 
0.01%, reflecting a recent price change of $2.42. The stock’s 52-week range, swinging
from $182.82 to $293.73, underscores its volatility and the dynamic market conditions
impacting the sector. As investors eye its forward P/E ratio of 17.47, they are 
likely weighing the company’s potential for growth against its current valuation.

A standout feature for potential investors is ResMed’s reported revenue growth of
10.80%, signaling robust performance and competitive positioning. The company’s 
strong return on equity at 25.25% further demonstrates its efficiency in generating
profits from shareholders’ investments. Additionally, with an EPS of $10.38, ResMed
showcases its ability to translate revenue into tangible earnings, an attractive
prospect for those prioritizing earnings performance.

The company’s free cash flow, amounting to over $1.4 billion, signifies its capability
to fund operations, reinvest in growth opportunities, and reward shareholders through
dividends. With a dividend yield of 1.14% and a conservative payout ratio of 22.47%,
ResMed provides a balanced approach to income generation for investors seeking both
growth and dividends.

Analyst sentiment towards ResMed is mixed, with 7 buy ratings, 10 hold ratings, 
and 1 sell rating. The stock’s target price range of $180.00 to $325.00, coupled
with an average target of $248.60, highlights a potential upside of 17.83%. This
projection positions ResMed as an enticing opportunity for investors looking for
growth in the healthcare domain.

Technical indicators present an intriguing picture: the stock’s RSI of 53.22 indicates
a neutral position, neither overbought nor oversold, while the MACD of 2.10, above
the signal line of 0.66, suggests a bullish trend. The 50-day moving average of 
$199.22, below the 200-day moving average of $232.01, may point to a potential rebound,
appealing to those inclined towards technical analysis for decision-making.

ResMed’s comprehensive portfolio of products and services, from sleep apnea diagnostic
devices to advanced healthcare software solutions, underscores its commitment to
innovation and patient care. The company’s strategic initiatives in cloud-based 
technologies and healthcare management position it well amidst evolving industry
demands and technological advancements.

Headquartered in San Diego, California, and founded in 1989, ResMed has consistently
demonstrated resilience and adaptability. As investors evaluate ResMed’s stock, 
the company’s innovative edge and financial health present a compelling case for
consideration in a diversified investment portfolio.

Share on:
